156 related articles for article (PubMed ID: 29517836)
1. Deletion of the C26 Methyl Substituent from the Bryostatin Analogue Merle 23 Has Negligible Impact on Its Biological Profile and Potency.
Zhao X; Kedei N; Michalowski A; Lewin NE; Keck GE; Blumberg PM
Chembiochem; 2018 May; 19(10):1049-1059. PubMed ID: 29517836
[TBL] [Abstract][Full Text] [Related]
2. Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review.
Raghuvanshi R; Bharate SB
Curr Top Med Chem; 2020; 20(12):1124-1135. PubMed ID: 32209043
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of the anti-chikungunya virus activity of novel bryostatin analogs confirms the existence of a PKC-independent mechanism.
Abdelnabi R; Staveness D; Near KE; Wender PA; Delang L; Neyts J; Leyssen P
Biochem Pharmacol; 2016 Nov; 120():15-21. PubMed ID: 27664855
[TBL] [Abstract][Full Text] [Related]
4. Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action.
Kedei N; Telek A; Michalowski AM; Kraft MB; Li W; Poudel YB; Rudra A; Petersen ME; Keck GE; Blumberg PM
Biochem Pharmacol; 2013 Feb; 85(3):313-24. PubMed ID: 23146662
[TBL] [Abstract][Full Text] [Related]
5. Function through synthesis-informed design.
Wender PA; Quiroz RV; Stevens MC
Acc Chem Res; 2015 Mar; 48(3):752-60. PubMed ID: 25742599
[TBL] [Abstract][Full Text] [Related]
6. The synthetic bryostatin analog Merle 23 dissects distinct mechanisms of bryostatin activity in the LNCaP human prostate cancer cell line.
Kedei N; Telek A; Czap A; Lubart ES; Czifra G; Yang D; Chen J; Morrison T; Goldsmith PK; Lim L; Mannan P; Garfield SH; Kraft MB; Li W; Keck GE; Blumberg PM
Biochem Pharmacol; 2011 Jun; 81(11):1296-308. PubMed ID: 21458422
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of a des-B-ring bryostatin analogue leads to an unexpected ring expansion of the bryolactone core.
Kraft MB; Poudel YB; Kedei N; Lewin NE; Peach ML; Blumberg PM; Keck GE
J Am Chem Soc; 2014 Sep; 136(38):13202-8. PubMed ID: 25207434
[TBL] [Abstract][Full Text] [Related]
8. Substitution on the A-ring confers to bryopyran analogues the unique biological activity characteristic of bryostatins and distinct from that of the phorbol esters.
Keck GE; Poudel YB; Welch DS; Kraft MB; Truong AP; Stephens JC; Kedei N; Lewin NE; Blumberg PM
Org Lett; 2009 Feb; 11(3):593-6. PubMed ID: 19113896
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamics simulations reveal ligand-controlled positioning of a peripheral protein complex in membranes.
Ryckbosch SM; Wender PA; Pande VS
Nat Commun; 2017 Feb; 8(1):6. PubMed ID: 28232750
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity.
Wender PA; Baryza JL; Brenner SE; DeChristopher BA; Loy BA; Schrier AJ; Verma VA
Proc Natl Acad Sci U S A; 2011 Apr; 108(17):6721-6. PubMed ID: 21415363
[TBL] [Abstract][Full Text] [Related]
11. Biological activity of the bryostatin analog Merle 23 on mouse epidermal cells and mouse skin.
Kelsey JS; Cataisson C; Chen J; Herrmann MA; Petersen ME; Baumann DO; McGowan KM; Yuspa SH; Keck GE; Blumberg PM
Mol Carcinog; 2016 Dec; 55(12):2183-2195. PubMed ID: 26859836
[TBL] [Abstract][Full Text] [Related]
12. The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development.
Ruan BF; Zhu HL
Curr Med Chem; 2012; 19(16):2652-64. PubMed ID: 22506770
[TBL] [Abstract][Full Text] [Related]
13. Biological profile of the less lipophilic and synthetically more accessible bryostatin 7 closely resembles that of bryostatin 1.
Kedei N; Lewin NE; Géczy T; Selezneva J; Braun DC; Chen J; Herrmann MA; Heldman MR; Lim L; Mannan P; Garfield SH; Poudel YB; Cummins TJ; Rudra A; Blumberg PM; Keck GE
ACS Chem Biol; 2013 Apr; 8(4):767-77. PubMed ID: 23369356
[TBL] [Abstract][Full Text] [Related]
14. Role of the C8 gem-dimethyl group of bryostatin 1 on its unique pattern of biological activity.
Keck GE; Poudel YB; Rudra A; Stephens JC; Kedei N; Lewin NE; Blumberg PM
Bioorg Med Chem Lett; 2012 Jun; 22(12):4084-8. PubMed ID: 22579485
[TBL] [Abstract][Full Text] [Related]
15. The bryostatin 1 A-ring acetate is not the critical determinant for antagonism of phorbol ester-induced biological responses.
Keck GE; Li W; Kraft MB; Kedei N; Lewin NE; Blumberg PM
Org Lett; 2009 Jun; 11(11):2277-80. PubMed ID: 19419164
[TBL] [Abstract][Full Text] [Related]
16. Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C.
Wender PA; Cribbs CM; Koehler KF; Sharkey NA; Herald CL; Kamano Y; Pettit GR; Blumberg PM
Proc Natl Acad Sci U S A; 1988 Oct; 85(19):7197-201. PubMed ID: 3174627
[TBL] [Abstract][Full Text] [Related]
17. Neristatin 1 provides critical insight into bryostatin 1 structure-function relationships.
Kedei N; Kraft MB; Keck GE; Herald CL; Melody N; Pettit GR; Blumberg PM
J Nat Prod; 2015 Apr; 78(4):896-900. PubMed ID: 25808573
[TBL] [Abstract][Full Text] [Related]
18. Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro.
DeChristopher BA; Loy BA; Marsden MD; Schrier AJ; Zack JA; Wender PA
Nat Chem; 2012 Sep; 4(9):705-10. PubMed ID: 22914190
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of Chromane-Based Bryostatin Analogues Prepared via Hydrogen-Mediated C-C Bond Formation: Potency Does Not Confer Bryostatin-like Biology.
Ketcham JM; Volchkov I; Chen TY; Blumberg PM; Kedei N; Lewin NE; Krische MJ
J Am Chem Soc; 2016 Oct; 138(40):13415-13423. PubMed ID: 27676096
[TBL] [Abstract][Full Text] [Related]
20. Designed PKC-targeting bryostatin analogs modulate innate immunity and neuroinflammation.
Abramson E; Hardman C; Shimizu AJ; Hwang S; Hester LD; Snyder SH; Wender PA; Kim PM; Kornberg MD
Cell Chem Biol; 2021 Apr; 28(4):537-545.e4. PubMed ID: 33472023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
